Aviva PLC lessened its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 19.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 129,955 shares of the biopharmaceutical company’s stock after selling 31,588 shares during the quarter. Aviva PLC owned about 0.06% […]
Incyte (NASDAQ:INCY – Free Report) had its target price lowered by Citigroup from $82.00 to $81.00 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the stock. StockNews.com upgraded shares of Incyte from a […]
Incyte (NASDAQ:INCY – Free Report) had its price objective lifted by Royal Bank of Canada from $63.00 to $65.00 in a research report report published on Wednesday, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock. INCY has been the subject of several other research reports. Morgan […]
JMP Securities lowered shares of Incyte (NASDAQ:INCY – Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. Other analysts also recently issued reports about the stock. William Blair reaffirmed an outperform rating on shares of Incyte in a report on […]
Incyte (NASDAQ:INCY – Get Free Report) had its price objective upped by investment analysts at BMO Capital Markets from $58.00 to $64.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential […]